Reversing Chemorefraction in Colorectal Cancer Cells by Controlling Mucin Secretion

Overview

Journal Elife

Specialty Biology

Date 2022 Feb 8

PMID 35131032

Authors

Gerard Cantero-Recasens

Josune Alonso-Maranon

Teresa Lobo-Jarne

Marta Garrido

Mar Iglesias

Lluis Espinosa

Vivek Malhotra

Affiliations

Soon will be listed here.

Abstract

Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy. We now formally show that CRC cells build a barrier to chemotherapeutics by increasing mucins' secretion. We show that low levels of KChIP3, a negative regulator of mucin secretion (Cantero-Recasens et al., 2018), is a risk factor for CRC patients' relapse in a subset of untreated tumours. Our results also reveal that cells depleted of KChIP3 are four times more resistant (measured as cell viability and DNA damage) to chemotherapeutics 5-fluorouracil + irinotecan (5-FU+iri.) compared to control cells, whereas KChIP3-overexpressing cells are 10 times more sensitive to killing by chemotherapeutics. A similar increase in tumour cell death is observed upon chemical inhibition of mucin secretion by the sodium/calcium exchanger (NCX) blockers (Mitrovic et al., 2013). Finally, sensitivity of CRC patient-derived organoids to 5-FU+iri. increases 40-fold upon mucin secretion inhibition. Reducing mucin secretion thus provides a means to control chemoresistance of mucinous CRC cells and other mucinous tumours.

Citing Articles

The value of predicting neoadjuvant chemotherapy early efficacy in nasopharyngeal carcinoma based on amide proton transfer imaging and diffusion weighted imaging.

Zhang Y, Li G, Chen J, Jiang M, Gao Y, Li K Quant Imaging Med Surg. 2024; 14(10):7330-7340.

PMID: 39429559 PMC: 11485347. DOI: 10.21037/qims-24-188.

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.

Cheraghi-Shavi T, Jalal R, Minuchehr Z PLoS One. 2023; 18(8):e0289535.

PMID: 37535601 PMC: 10399784. DOI: 10.1371/journal.pone.0289535.

Tetraspanin-8 sequesters syntaxin-2 to control biphasic release propensity of mucin granules.

Wojnacki J, Lujan A, Brouwers N, Aranda-Vallejo C, Bigliani G, Pena Rodriguez M Nat Commun. 2023; 14(1):3710.

PMID: 37349283 PMC: 10287693. DOI: 10.1038/s41467-023-39277-9.

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.

Arikan R, Atci M, Ay S, Ayhan M, Demircan N, Telli T Oncol Lett. 2023; 25(5):208.

PMID: 37123028 PMC: 10131277. DOI: 10.3892/ol.2023.13795.

View from the Biological Property: Insight into the Functional Diversity and Complexity of the Gut Mucus.

He C, Gao H, Xin S, Hua R, Guo X, Han Y Int J Mol Sci. 2023; 24(4).

PMID: 36835646 PMC: 9960128. DOI: 10.3390/ijms24044227.

References

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

Kamnerdsupaphon P, Lorvidhaya V, Chitapanarux I, Tonusin A, Sukthomya V . FOLFIRI chemotherapy for metastatic colorectal cancer patients. J Med Assoc Thai. 2007; 90(10):2121-7. View

Sato T, Stange D, Ferrante M, Vries R, van Es J, van den Brink S . Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011; 141(5):1762-72. DOI: 10.1053/j.gastro.2011.07.050. View

Podhorecka M, Skladanowski A, Bozko P . H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. J Nucleic Acids. 2010; 2010. PMC: 2929501. DOI: 10.4061/2010/920161. View

van Putten J, Strijbis K . Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer. J Innate Immun. 2017; 9(3):281-299. PMC: 5516414. DOI: 10.1159/000453594. View

Rossi A, Sears P, Davis C . Ca2+ dependency of 'Ca2+-independent' exocytosis in SPOC1 airway goblet cells. J Physiol. 2004; 559(Pt 2):555-65. PMC: 1665132. DOI: 10.1113/jphysiol.2004.070433. View

Abdullah L, Conway J, Cohn J, Davis C . Protein kinase C and Ca2+ activation of mucin secretion in airway goblet cells. Am J Physiol. 1997; 273(1 Pt 1):L201-10. DOI: 10.1152/ajplung.1997.273.1.L201. View

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D . ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. DOI: 10.1093/annonc/mdw235. View

Pelaseyed T, Bergstrom J, Gustafsson J, Ermund A, Birchenough G, Schutte A . The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014; 260(1):8-20. PMC: 4281373. DOI: 10.1111/imr.12182. View

10.

Adler K, Tuvim M, Dickey B . Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne). 2013; 4:129. PMC: 3776272. DOI: 10.3389/fendo.2013.00129. View

11.

Mayo C, Lloreta J, Real F, Mayol X . In vitro differentiation of HT-29 M6 mucus-secreting colon cancer cells involves a trychostatin A and p27(KIP1)-inducible transcriptional program of gene expression. J Cell Physiol. 2007; 212(1):42-50. DOI: 10.1002/jcp.20999. View

12.

Iwamoto T, Inoue Y, Ito K, Sakaue T, Kita S, Katsuragi T . The exchanger inhibitory peptide region-dependent inhibition of Na+/Ca2+ exchange by SN-6 [2-[4-(4-nitrobenzyloxy)benzyl]thiazolidine-4-carboxylic acid ethyl ester], a novel benzyloxyphenyl derivative. Mol Pharmacol. 2004; 66(1):45-55. DOI: 10.1124/mol.66.1.45. View

13.

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

14.

Thornton D, Rousseau K, McGuckin M . Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol. 2007; 70:459-86. DOI: 10.1146/annurev.physiol.70.113006.100702. View

15.

Sheehan J, Kirkham S, Howard M, Woodman P, Kutay S, Brazeau C . Identification of molecular intermediates in the assembly pathway of the MUC5AC mucin. J Biol Chem. 2004; 279(15):15698-705. DOI: 10.1074/jbc.M313241200. View

16.

Kufe D . Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9(12):874-85. PMC: 2951677. DOI: 10.1038/nrc2761. View

17.

Jonckheere N, Skrypek N, Van Seuningen I . Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014; 1846(1):142-51. DOI: 10.1016/j.bbcan.2014.04.008. View

18.

Niu C, Watanabe Y, Ono K, Iwamoto T, Yamashita K, Satoh H . Characterization of SN-6, a novel Na+/Ca2+ exchange inhibitor in guinea pig cardiac ventricular myocytes. Eur J Pharmacol. 2007; 573(1-3):161-9. DOI: 10.1016/j.ejphar.2007.06.033. View

19.

Watanabe Y, Koide Y, Kimura J . Topics on the Na+/Ca2+ exchanger: pharmacological characterization of Na+/Ca2+ exchanger inhibitors. J Pharmacol Sci. 2006; 102(1):7-16. DOI: 10.1254/jphs.fmj06002x2. View

20.

Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Sole L . IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer. Mol Cell. 2019; 75(4):669-682.e5. PMC: 6715775. DOI: 10.1016/j.molcel.2019.05.036. View